CytomX CEO Disposes $764K of Shares as Company Advances Clinical and Financing Plans
CytomX Therapeutics CEO Sean A. McCarthy sold 118,969 shares on March 17, 2026, at $6.423 per share for $764,137 to meet tax obligations tied to the vesting of restricted stock units. The transaction leaves him with just over 1.07 million shares directly and an additional indirect holding in a family trust. The move occurs as the company advances a…